logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
11/02/2026
The total trading volume of the Shanghai and Shenzhen stock exchanges exceeded 1 trillion yuan, a decrease of 70.5 billion yuan from the previous day at the same time.
Latest
2 m ago
Hunan highway enhances charging facilities with encryption, upgrades intelligent service areas.
3 m ago
Reyvow and Ajovy approved in China.
4 m ago
The company Leikai's ustekinumab and ustekinumab (generic name: Migezhu monoclonal antibody) have been approved by the National Medical Products Administration for the treatment of moderate to severe active Crohn's disease in adults and moderate to severe active ulcerative colitis in adults. Ustekinumab (Migezhu monoclonal antibody injection (intravenous infusion)) and ustekinumab (Migezhu monoclonal antibody injection) are a specific IgG4 monoclonal antibody targeting the interleukin-23 (IL-23) p19 subunit, which selectively inhibits the IL-23 pathway regulating the immune inflammatory response driven by it.
4 m ago
The institution suggests holding high-dividend stocks during the holidays, and the Hong Kong stock market ETF has rebounded after bottoming out.
4 m ago
The general manager of Huaxia Fund, Mr. Li Yimei, is optimistic about value stocks and large-cap blue-chip stocks this year.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.